Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety studySherko Kuemmel, Miguel Martín, Flavia Morales-Vásquez et al.|Breast Cancer Research and Treatment|2021Cited by 23
Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysisSherko Kümmel, Miguel Martín, Carlo Tondini et al.|Annals of Oncology|2018Cited by 3
Subcutaneous Trastuzumab with Pertuzumab and Docetaxel in HER2-Positive Metastatic Breast Cancer: Final Analysis of MetaPHER, A Phase 3b Single-Arm Safety StudySherko Kümmel, Miguel Martín, Carlo Tondini et al.|Research Square|2020Cited by 1
Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER studySherko Kümmel, Miguel Martín, Estefanía Monturus et al.|Cancer Research|2020Cited by 0